Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

Style" type="disc">
  • The Company is still in the development stage and has not generated any revenues. From inception through June 30, 2010, it incurred net losses and negative cash flows from operating activities of approximately $55.7 million and $41.6 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At June 30, 2010, the Company had cash and cash equivalents of approximately $4.5 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activity and to complete its plan of operations through December 31, 2010. At the Company's present level of activities, the Company's cash and cash equivalents are believed, at this time, to be sufficient to fund its operations only into the fourth quarter of 2010. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations. The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversel
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
    2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
    3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
    4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
    5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
    6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
    7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
    8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
    9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
    10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... , Aug. 27, 2015  MiMedx Group, Inc. (NASDAQ: ... utilizing human amniotic tissue and patent-protected processes to ... the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, ... and corrected the multiple inaccuracies in the press ... regarding the recent rulings from the Patent Trial ...
    (Date:8/27/2015)...  Hill-Rom Holdings, Inc., (NYSE: HRC ) invites ... Morgan Stanley Global Healthcare Conference on September 16, 2015, ... to listen to the live discussion via the internet ... https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded replay of ... conclusion of the live event and accessible via the ...
    (Date:8/27/2015)... 27, 2015 Major pharmaceutical and medical device companies ... conference in Philadelphia on Oct. 20, ... Tom Hagy of HB Litigation Conferences has announced. ... website at http://litigationconferences.com/?p=31886 The program is ... & Mahoney and Michelle Hart Yeary of Dechert ...
    Breaking Medicine Technology:MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3
    ... Systems ( http://www.dcmsys.com ), healthcare IT company and teleradiology ... the Vendor Neutral Archive (VNA) vendor of choice by ... Dicom Systems, VNA works with any existing ... current storage to your PACS archive at any time, ...
    ... LANSING, Mich., Jan. 16, 2012  Neogen Corporation (NASDAQ: ... detect precise amounts of the mycotoxin zearalenone in grain ... wide variety of reproductive problems if eaten by livestock. ... to the company,s unequaled line of simple, quick, and ...
    Cached Medicine Technology:ONRAD, Inc. Chooses Dicom Systems' Vendor Neutral Archive 2Neogen Develops Simple, Precise Test for Mold Toxin Zearalenone 2
    (Date:8/27/2015)... ... 27, 2015 , ... In mid-May, Logistics Trust, Inc. (“Logistics ... launch of its Doobster platform, a HIPAA-compliant mobile application that allows medical marijuana ... phones and tablets. Well, Doobster, “The App That Delivers!” is here! ...
    (Date:8/27/2015)... , ... August 27, 2015 , ... ... Summit , scheduled for October 27-29, 2015 in San Jose, CA. The ... will primarily focus on the void that exists where battery development and energy ...
    (Date:8/27/2015)... ... ... In addition to its existing Doctor of Philosophy in Leadership and Doctor of ... campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of Nursing Practice ... the highest level of clinical nursing practice. , “Our vision is to graduate ...
    (Date:8/27/2015)... ... ... Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, will open a ... be located at US Highway 19 North and Highlands Boulevard, less than eight miles from ... the project is slated to begin in September 2015. , The new 24-bed ...
    (Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named ... the platforms required not only to effectively deliver, curate and administer great programs, but ... Inc. , For six consecutive years, NetDimensions has maintained its position on this ...
    Breaking Medicine News(10 mins):Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3
    ... estimate that fully 95 percent of our DNA represents ... the journal Cell researchers at The Wistar ... the discovery of the ability of long non-coding RNA ... long ncRNA molecules may represent so-called gene enhancer elementsshort ...
    ... used as a marker of health and well-being in unborn ... currently available to differentiate between a small, healthy fetus and ... significant limitations. What if they were improved? Would it save ... need medical intervention because their fetuses might just be small ...
    ... Fox Foundation for Parkinson,s Research announced awards totaling approximately ... pre-clinical therapeutic development projects. The funding includes $2.5 million ... Intervention Awards, one of the Foundation,s Edmond J. Safra ... the 2010 Clinical Intervention Awards are: , Charlotte ...
    ... Oct. 6, 2010 A set of proteins found ... way to diagnose Alzheimer,s disease, researchers at UT Southwestern Medical ... An analysis of the proteins, plus a clinical exam, ... percent accurate in ruling it out in people without the ...
    ... HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay News) -- ... received ,hands-only, cardiopulmonary resuscitation (CPR) from a bystander were ... received no CPR or conventional CPR with mouth-to-mouth breathing. ... only is ,hands-only, CPR -- in which the rescuer ...
    ... Mozes HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay ... apnea can subtly alter the shape of a patient,s face ... treatment, called continuous positive airway pressure (CPAP) can help relieve ... found possible craniofacial change [as a result of] long-term CPAP ...
    Cached Medicine News:Health News:Wistar researchers discover new class of objects encoded within the genome 2Health News:Wistar researchers discover new class of objects encoded within the genome 3Health News:MFM researcher earns $3.7M NIH grant to study preterm birth 2Health News:MJFF announces over $10 million in funding for clinical and pre-clinical PD research 2Health News:Blood test could diagnose Alzheimer's disease, UT Southwestern researchers find 2Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 2Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 3Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 4Health News:Sleep Apnea Mask May Cause Subtle Facial Changes 2Health News:Sleep Apnea Mask May Cause Subtle Facial Changes 3
    ... and negative whole blood control to test ... solubility tests and hemoglobin electrophoresis. Sickle-Chex is ... manufacturers' solubility kits. Sickle-Chex is packaged in ... vial dispenses an accurate sample volume. No ...
    ... three-part differential control assayed for all parameters on ... Series, AcT/AcT diff/AcT diff2, MD Series and ONYX ... 1800; ABX Micros 60; and Diatron Abacus and ... stability of 30 days and a six-month closed-vial ...
    ... Cell-Chex Auto is a whole blood ... of hematology instruments that measure automated blood ... The assay provides total RBC and WBC ... and Sapphire, Beckman Coulter LH750/LH 755 (levels ...
    iSleep 20i is an advanced high performance CPAP with outstanding self-adjusting i‑technology....
    Medicine Products: